Adagio Medical Holdings (ADGM)
NASDAQ:ADGM
Want to see ADGM full AI Analyst Report?
ADGM Stock Chart & Stats
$1.08
-$0.11(-9.46%)
At close: 4:00 PM EST
$1.08
-$0.11(-9.46%)
Day’s Range― - ―
52-Week Range$0.68 - $2.58
Previous Close$1.04
Volume669.05K
Average Volume (3M)152.12K
Market Cap
$15.10M
Enterprise Value$21.84M
Total Cash (Recent Filing)$12.91M
Total Debt (Recent Filing)$24.09M
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Aug 19, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap1.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.85
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$3.33Price Target Upside208.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone: PMA Submission For VCLASA submitted PMA is a durable structural step toward U.S. commercialization. Backed by Breakthrough Device designation and pivotal IDE data, the PMA materially increases the probability of market entry and gradual revenue generation in the sizeable VT market if approval follows.
Robust Pivotal Clinical ResultsStrong safety and effectiveness metrics reduce adoption friction among electrophysiologists and support reimbursement conversations. Durable clinical credibility is a key structural advantage for converting trials into guideline adoption and sustained commercial uptake over months to years.
Pipeline Scalability: IDE Expansion For Next‑gen VCLAS UltraAn IDE expansion for a next‑gen catheter indicates product roadmap depth and potential for shorter procedures and easier manufacturing. These features can improve unit economics, broaden adoption across centers, and support durable commercial scaling if clinical validation continues.
Bears Say
Minimal Revenue And Negative Gross ProfitLack of meaningful commercial revenue and negative gross margins imply the product is not yet self-sustaining. This structural gap means profitability depends on successful regulatory approval and commercial launch; until then, the business requires external funding to bridge fixed costs.
Sustained Negative Operating And Free Cash FlowPersistent negative OCF and FCF constrain runway and strategic flexibility. Even with some improvement, ongoing cash burn necessitates external financing, which can dilute shareholders or impose restrictive covenants, affecting execution of commercialization plans over the next several quarters.
Nasdaq Minimum Bid Price Noncompliance RiskFormal noncompliance introduces a real delisting threat and potential reverse split. Delisting risk can reduce liquidity, narrow the investor base, raise cost of capital, and impair the company's ability to raise financing needed to support regulatory commercialization milestones.
Adagio Medical Holdings News
ADGM FAQ
What was Adagio Medical Holdings’s price range in the past 12 months?
Adagio Medical Holdings lowest stock price was $0.68 and its highest was $2.58 in the past 12 months.
What is Adagio Medical Holdings’s market cap?
Adagio Medical Holdings’s market cap is $15.10M.
When is Adagio Medical Holdings’s upcoming earnings report date?
Adagio Medical Holdings’s upcoming earnings report date is Aug 19, 2026 which is in 58 days.
How were Adagio Medical Holdings’s earnings last quarter?
Adagio Medical Holdings released its earnings results on May 12, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.02.
Is Adagio Medical Holdings overvalued?
According to Wall Street analysts Adagio Medical Holdings’s price is currently Undervalued.
Does Adagio Medical Holdings pay dividends?
Adagio Medical Holdings does not currently pay dividends.
What is Adagio Medical Holdings’s EPS estimate?
Adagio Medical Holdings’s EPS estimate is -0.31.
How many shares outstanding does Adagio Medical Holdings have?
Adagio Medical Holdings has 22,210,459 shares outstanding.
What happened to Adagio Medical Holdings’s price movement after its last earnings report?
Adagio Medical Holdings reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -1.915%.
Which hedge fund is a major shareholder of Adagio Medical Holdings?
Currently, no hedge funds are holding shares in ADGM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adagio Medical Holdings
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
ADGM Stock 12 Month Forecast
Average Price Target
$3.33
▲(208.64% Upside)
Technical Analysis
Ownership Overview
45.47% Insiders
0.47% Mutual Funds
41.61% Other Institutional Investors
12.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---